By Helen Mooney2007-09-20T00:00:00
When the High Court upheld NICE guidance on Alzheimer's drugs, it was seen as an endorsement of its fairness and credibility. But unless the public is better informed of resource issues, unrealistic demands for new drugs will continue to be an issue, writes Helen Mooney
With a HSJ subscription you’ll unlock:
HSJ is part of Wilmington Healthcare Limited. Company number 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Registered in England and Wales. Company registration 30158470
Site powered by Webvision Cloud